<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title>International Journal of Molecular Sciences</journal-title>
<abbrev-journal-title>Int. J. Mol. Sci.</abbrev-journal-title>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>Molecular Diversity Preservation International (MDPI)</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3390/ijms11030880</article-id>
<article-id pub-id-type="publisher-id">ijms-11-00880</article-id>
<article-categories>
<subj-group>
<subject>Article</subject></subj-group></article-categories>
<title-group>
<article-title>QSAR Studies on Andrographolide Derivatives as α-Glucosidase Inhibitors</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Xu</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="af1-ijms-11-00880">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Huang</surname><given-names>Sichao</given-names></name><xref ref-type="aff" rid="af1-ijms-11-00880">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Luo</surname><given-names>Haibin</given-names></name><xref ref-type="aff" rid="af2-ijms-11-00880">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Guoji</given-names></name><xref ref-type="aff" rid="af1-ijms-11-00880">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Bao</surname><given-names>Jiaolin</given-names></name><xref ref-type="aff" rid="af1-ijms-11-00880">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Cai</surname><given-names>Shaohui</given-names></name><xref ref-type="aff" rid="af1-ijms-11-00880">1</xref><xref ref-type="corresp" rid="c1-ijms-11-00880">*</xref></contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Yuqiang</given-names></name><xref ref-type="aff" rid="af1-ijms-11-00880">1</xref><xref ref-type="corresp" rid="c1-ijms-11-00880">*</xref></contrib></contrib-group>
<aff id="af1-ijms-11-00880">
<label>1</label> Pharmacy College, Jinan University, Guangzhou, 510632, China; E-Mails: 
<email>goldstar_8209@163.com</email> (J.X.); 
<email>sichaohuang.cn@gmail.com</email> (S.H.); 
<email>1027559485@qq.com</email> (G.L.); 
<email>23854695@qq.com</email> (J.B.)</aff>
<aff id="af2-ijms-11-00880">
<label>2</label> School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510275, China; E-Mail: 
<email>luohb77@mail.sysu.edu.cn</email> (H.L.)</aff>
<author-notes>
<corresp id="c1-ijms-11-00880">
<label>*</label> Authors to whom correspondence should be addressed; E-Mail: 
<email>csh5689@sina.com</email> (S.C.); 
<email>yuqiangwang2001@yahoo.com</email> (Y.W.).</corresp></author-notes>
<pub-date pub-type="epub">
<day>2</day>
<month>3</month>
<year>2010</year></pub-date>
<pub-date pub-type="collection">
<year>2010</year></pub-date>
<volume>11</volume>
<issue>3</issue>
<fpage>880</fpage>
<lpage>895</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>1</month>
<year>2010</year></date>
<date date-type="rev-recd">
<day>2</day>
<month>2</month>
<year>2010</year></date>
<date date-type="accepted">
<day>3</day>
<month>2</month>
<year>2010</year></date></history>
<permissions>
<copyright-statement>© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.</copyright-statement>
<copyright-year>2010</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p></license></permissions>
<abstract>
<p>Andrographolide derivatives were shown to inhibit α-glucosidase. To investigate the relationship between activities and structures of andrographolide derivatives, a training set was chosen from 25 andrographolide derivatives by the principal component analysis (PCA) method, and a quantitative structure-activity relationship (QSAR) was established by 2D and 3D QSAR methods. The cross-validation <italic>r</italic><sup>2</sup> (0.731) and standard error (0.225) illustrated that the 2D-QSAR model was able to identify the important molecular fragments and the cross-validation <italic>r</italic><sup>2</sup> (0.794) and standard error (0.127) demonstrated that the 3D-QSAR model was capable of exploring the spatial distribution of important fragments. The obtained results suggested that proposed combination of 2D and 3D QSAR models could be useful in predicting the α-glucosidase inhibiting activity of andrographolide derivatives.</p></abstract>
<kwd-group>
<kwd>andrographolide</kwd>
<kwd>QSAR</kwd>
<kwd>α-glucosidase</kwd>
<kwd>HQSAR</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<label>1.</label>
<title>Introduction</title>
<p><italic>Andrographis paniculate</italic> is a plant widely used as a traditional Chinese medicine in China, India, and other Asian countries [<xref ref-type="bibr" rid="b1-ijms-11-00880">1</xref>,<xref ref-type="bibr" rid="b2-ijms-11-00880">2</xref>]. Extracts and constituents of <italic>Andrographis paniculate</italic> exhibit broad pharmacological activities, such as anti-bacterial, ant-malarial, anti-inflammatory, anti-tumor, immunological regulation, and hepatoprotective effects [<xref ref-type="bibr" rid="b3-ijms-11-00880">3</xref>–<xref ref-type="bibr" rid="b12-ijms-11-00880">12</xref>]. Lately, some andrographolide derivatives were reported to decrease blood glucose level by inhibiting α-glucosidase [<xref ref-type="bibr" rid="b13-ijms-11-00880">13</xref>,<xref ref-type="bibr" rid="b14-ijms-11-00880">14</xref>]. It has been well known that α-glucosidase is a key enzyme in the absorption of sugar in the small intestine mucous membrane, and its activity is closely related to blood glucose levels. Studies also indicated that α-glucosidase might be involved in diabetes [<xref ref-type="bibr" rid="b15-ijms-11-00880">15</xref>–<xref ref-type="bibr" rid="b20-ijms-11-00880">20</xref>]. Accordingly, α-glucosidase is considered an important target for the design of antidiabetic drugs. Recently, efforts had been made in modification and synthesis of novel andrographolide derivatives to find more potent and safer α-glucosidase inhibitors. Knowledge about the relationships between structures of andrographolide derivatives and their inhibitory activities on α-glucosidase could greatly facilitate the drug discovery process.</p>
<p>QSAR [<xref ref-type="bibr" rid="b21-ijms-11-00880">21</xref>] has been widely used for years to provide quantitative analysis of structure and activity relationships of compounds. Statistical methods are applied in QSAR modeling to establish correlations between chemical structures and their biological activities. Once validated, the findings can be used to predict activities of untested compounds. Recently, computer-assisted drug design based on QSAR has been successfully employed to develop new drugs for the treatment of cancer, AIDS, SARS, and other diseases [<xref ref-type="bibr" rid="b22-ijms-11-00880">22</xref>–<xref ref-type="bibr" rid="b29-ijms-11-00880">29</xref>]. With the availability of large commercial databases and highly efficient programs including Sybyl, Discovery studio, MOE and so on, it is estimated that QSAR modeling as a tool could remarkably reduces the cost of drug discovery [<xref ref-type="bibr" rid="b30-ijms-11-00880">30</xref>].</p>
<p>In this study, 2D QSAR models were constructed to describe the important fragments in andrographolide derivatives and 3D QSAR models were established to explore the spatial distribution of important groups. The combination of 2D and 3D QSAR models could better summarize the QSAR of andrographolide derivatives in inhibiting α-glucosidase.</p></sec>
<sec sec-type="methods">
<label>2.</label>
<title>Computational Methods</title>
<sec sec-type="methods">
<label>2.1.</label>
<title>Database and Software</title>
<p>The structures and inhibitory activities (IC50) of 25 andrographolide derivatives (<xref ref-type="fig" rid="f1-ijms-11-00880">Figure 1</xref>) were collected from the literature, and served as the database to build QSAR models [<xref ref-type="bibr" rid="b13-ijms-11-00880">13</xref>,<xref ref-type="bibr" rid="b14-ijms-11-00880">14</xref>,<xref ref-type="bibr" rid="b31-ijms-11-00880">31</xref>]. PLogIC50 was used as the dependent variable of QSAR model. PCA, HQSAR, CoMFA, CoMSIA were performed by Sybyl7.03 (Tripos Co., LTD) program.</p></sec>
<sec>
<label>2.2.</label>
<title>Training Set Selection</title>
<p>Principle Component Analysis (PCA), employed to select the training set, could be applied to explain the differences among the 25 andrographolide derivatives through diversities of the structures’ parameters and to exhibit their distribution on a 2D plot [<xref ref-type="bibr" rid="b32-ijms-11-00880">32</xref>]. Furthermore, the most descriptive compounds (MDC) or the largest minimum distance (LMD) methods were applied to select the training set according to the distribution of these compounds.</p></sec>
<sec>
<label>2.3.</label>
<title>Generation and Validation of the 2D QSAR Model</title>
<p>Hologram QSAR (HQSAR) offers the ability to rapidly generate QSAR models of high statistical quality and predicted value by SYBYL line notation (SLN), cyclic redundancy check (CRC) and partial least squares (PLS) [<xref ref-type="bibr" rid="b33-ijms-11-00880">33</xref>–<xref ref-type="bibr" rid="b35-ijms-11-00880">35</xref>]. The premise of HQSAR is that since the structure of a molecule is encoded within its 2D fingerprint and that structure is the key determinant of all molecular properties (including biological activity), it should be possible to predict the activity of a molecule from its fingerprint.</p>
<p>The training set was used to establish 2D-QSAR model by HQSAR, and the best 2D-QSAR model was applied by the criterion of cross-validation R<sup>2</sup>. The test set’s biological activity was predicted by the best 2D-QSAR model, whose predictability was validated by correlation coefficient between the predicted and experimental values. The most common structure (MCS) could be calculated by HQSAR. Based on the MCS of andrographolide derivatives, the contributions of molecules’ fragments to biological activity should be analyzed for describing the QSAR of andrographolide derivatives as α-glucosidase inhibitors.</p></sec>
<sec>
<label>2.4.</label>
<title>Generation and Validation of the 3D QSAR Model</title>
<p>The three-D QSAR model applies PLS to explore the relationships between the physicochemical variables and biological activity. Cross-validation is used to estimate the QSAR model’s predictability. In general, a LOO cross-validated coefficient Q<sup>2</sup> (higher than 0.5) can be considered as statistically high predictive ability [<xref ref-type="bibr" rid="b36-ijms-11-00880">36</xref>]. CoMFA, which is widely utilized in 3D-QSAR research, claims that if a group of similar compounds are ligands of the same receptor, their bioactivities depend on the differences of the molecules’ fields surrounding them [<xref ref-type="bibr" rid="b37-ijms-11-00880">37</xref>]. CoMFA can exhibit a contour map in a 3D graph, which makes it easier to distinguish differences between compounds with strong and weak activities. CoMSIA is another 3D-QSAR method that adopts a Gaussian function instead of traditional Coulomb and Lennard-Jones’ function used in CoMFA [<xref ref-type="bibr" rid="b38-ijms-11-00880">38</xref>]. Therefore, CoMSIA efficiently avoids the shortcomings of CoMFA in which only the steric and electrostatic fields are used. The leave-one-out (LOO) method is employed to validate the predictability of the models and Y-Randomization test is used to validate the robustness of the models [<xref ref-type="bibr" rid="b39-ijms-11-00880">39</xref>].</p>
<p>In this study, CoMFA and CoMSIA were both utilized to generate 3D-QSAR models, and then the relative higher predictive 3D-QSAR models were selected by comparison. Subsequently, the selected models were further optimized by the Focusing method [<xref ref-type="bibr" rid="b40-ijms-11-00880">40</xref>]. This method describes the different contributions of different grids in CoMFA and CoMSIA to the bioactivities of the compounds by weighting, which was expected to selectively enhance or impair the contributions of different grids and improve the resolution. Moreover, the biological activities of test set were predicted by the optimized QSAR model. The best QSAR model was determined by comparing the parameters of the model and correlation between the predicted and experimental values of the test sets.</p></sec></sec>
<sec sec-type="discussion">
<label>3.</label>
<title>Result and Discussion</title>
<sec>
<label>3.1.</label>
<title>Training Set Selection</title>
<p>The selection of the training set is one of the most important steps in QSAR modeling, since the establishment and optimization of a QSAR model are based on this training set. Predictability and applicability of a QSAR model also depend on the training set selection [<xref ref-type="bibr" rid="b41-ijms-11-00880">41</xref>,<xref ref-type="bibr" rid="b42-ijms-11-00880">42</xref>]. Usually, the compounds serving as the training set should have three characteristics: (1) maximum structural diversity; (2) maximum activity diversity; (3) similarity of interactions [<xref ref-type="bibr" rid="b43-ijms-11-00880">43</xref>]. Besides, both molecular structures and biological activities of the test set should be covered by the ranges of the training set. In this research, PCA was applied to select a training set from among 25 andrographolide derivatives. PCA is a statistical technique useful for summarizing all the information encoded in the structures of compounds. It is also very helpful for understanding the distribution of the compounds.</p>
<p>The distribution pattern of the 25 andrographolide derivatives is shown in <xref ref-type="fig" rid="f2-ijms-11-00880">Figure 2</xref>. There were different population densities in the Figure. Eighteen compounds (<bold>1</bold>, <bold>3</bold>–<bold>8</bold>, <bold>11</bold>, <bold>13</bold>, <bold>16</bold>–<bold>21</bold> and <bold>23</bold>–<bold>25</bold>) were selected as the raining set by the MDC method. The rest of them (compounds <bold>2</bold>, <bold>9</bold>, <bold>10</bold>, <bold>14</bold>, <bold>15</bold> and <bold>22</bold>) were used as the test set whose biological activities were covered by the training set.</p></sec>
<sec>
<label>3.2.</label>
<title>Establishment and Validation of 2D-QSAR Model</title>
<p>The best cross-validation r<sup>2</sup> (0.731) and standard error (0.225) illustrated that the 2D-QSAR model could be applied to predict the biological activity of andrographolide derivatives as α-glucosidase inhibitors. The predicted and experimental biological activities of andrographolide derivatives are shown in <xref ref-type="table" rid="t1-ijms-11-00880">Table 1</xref>. The results of the correlation coefficient R<sup>2</sup>, standard error of the training set (0.840, 0.174) and test set (0.949, 0.104) suggested that the 2D-QSAR model could be used to explain the QSAR of andrographolide derivatives as α-glucosidase inhibitors.</p>
<p>Furthermore, three key fragments (<xref ref-type="fig" rid="f3-ijms-11-00880">Figure 3</xref>) were selected according to PLS coefficient. The predicted activity = 
<inline-formula>
<mml:math>
<mml:mrow>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mn>0</mml:mn></mml:msub>
<mml:mo>+</mml:mo>
<mml:munder>
<mml:mo>∑</mml:mo>
<mml:mi>i</mml:mi></mml:munder>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>i</mml:mi></mml:msub>
<mml:mo>×</mml:mo>
<mml:msub>
<mml:mi>b</mml:mi>
<mml:mi>i</mml:mi></mml:msub>
<mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> where <italic>C<sub>0</sub></italic> = the offset, <italic>C<sub>i</sub></italic> = the PLS coefficient associated with bin I in the hologram, <italic>b<sub>i</sub></italic>= the number of fragments hashed into bin <italic>i</italic>.</p>
<p>The PLS coefficient was the standardization for judging which fragment was the key fragment. The larger the PLS coefficient, the more important the fragment was for andrographolide derivatives’ biological activity. According to the criterion, C (=C©C)C=C or C[1]:C:C:C(:C:C:@1)C=C attached to C<sub>3</sub> of andrographolide (<xref ref-type="fig" rid="f4-ijms-11-00880">Figure 4</xref>) and C[1]:N:C:C(:C:C:@1)C(=C)O attached to C<sub>17</sub> of andrographolide were suggested as the key fragments.</p></sec>
<sec>
<label>3.3.</label>
<title>Establishment and Validation of the 3D-QSAR Model</title>
<p>The 18 compounds were energy minimized, added charges and aligned (<xref ref-type="fig" rid="f5-ijms-11-00880">Figure 5</xref>). CoMFA and CoMSIA were used to develop a number of QSAR models based on the properties of compounds belonging to different fields (steric, electrostatic, hydrophobic, H-donor and acceptor, <xref ref-type="table" rid="t2-ijms-11-00880">Table 2</xref>). Since the QSAR model was employed to predict unknown compounds’ activity, the model’s predictability was the criterion to judge which QSAR model was the best. Predictability of a QSAR model was not only expressed by cross-validation (q<sup>2</sup>) but also by validation of the test set. The results illustrated that four models (<bold>4</bold>, <bold>8</bold>, <bold>10</bold> and <bold>11</bold>) had the top four predictabilities, so the Focus method was then applied to optimize these models, and further improved predictability for model <bold>4</bold>, <bold>10</bold> and <bold>11</bold>, but not for model 8. Among these models (model <bold>8</bold>, <bold>13</bold>, <bold>15</bold> and <bold>16</bold>), model <bold>16</bold> exhibited the best predictability as indicated by the highest Q2 value. Predictability of these models (<bold>8</bold>, <bold>13</bold>, <bold>15</bold> and <bold>16</bold>) was further evaluated using a test set. Model <bold>16</bold> also provided the best prediction with a correlation coefficient R<sup>2</sup> (0.941) (<xref ref-type="table" rid="t3-ijms-11-00880">Table 3</xref>). Overall, this model represented the best QSAR model (q<sup>2</sup> = 0.794, R<sup>2</sup><sub>cv</sub> = 0.915, SE<sub>cv</sub> = 0.127, R<sup>2</sup><sub>test set</sub> = 0.941, SE<sub>test set</sub> = 0.104). Y-Randomization test (q<sup>2</sup> = 0.199) suggested that the model also had a good robustness. <xref ref-type="table" rid="t4-ijms-11-00880">Table 4</xref> showed Comparison between predicted PLogIC50 of database and experimental values by using Model <bold>16</bold>.</p>
<p>Model <bold>16</bold> used steric field, hydrophobic field and H-acceptor field together to describe the relationship between activities and structures of andrographolide derivatives. H-bond receptive atoms and groups in the region marked by blue lines (<xref ref-type="fig" rid="f6-ijms-11-00880">Figure 6</xref>) were favorable for the activities of the compounds, while the atoms and groups in the region marked by yellow lines impaired the activities. Hydrophobic groups were desirable in the region marked with blue lines but not the region marked by dark lines (<xref ref-type="fig" rid="f7-ijms-11-00880">Figure 7</xref>). In addition, the activities of the andrographolide derivatives were enhanced by the presence of steric groups in the region marked by purple lines instead of the region marked by green lines (<xref ref-type="fig" rid="f8-ijms-11-00880">Figure 8</xref>). The compounds with structures fitting well into the 3D contour maps derived from the model <bold>16</bold> usually exhibited potent inhibitory activity (e.g., compounds <bold>20</bold>, <bold>21</bold>, <bold>22</bold> and <bold>23</bold>). In contrast, weak inhibitors such as compounds <bold>3</bold>, <bold>4</bold>, <bold>13</bold> and <bold>16</bold> did not have a good fit to the 3D contour maps.</p>
<p>Compound <bold>21</bold> (potent α-glucosidase inhibitor PLogIC<sub>50</sub> = 5.222) was layed in the 3D contour maps of model <bold>16</bold> to illustrate the key groups (marked by red dashed lines in <xref ref-type="fig" rid="f5-ijms-11-00880">Figures 5</xref>, <xref ref-type="fig" rid="f6-ijms-11-00880">6</xref>, and <xref ref-type="fig" rid="f7-ijms-11-00880">7</xref>) correlating with biological activity. C[1]:N:C:C(:C:C:@1)C(=C)O was a key group in all the 3D contour maps (steric, H-accept, hydrophobic) and C[1]:C:C:C(:C:C:@1)C=C was a key group in both steric and hydrophobic 3D contour maps. Both the groups were also calculated as key groups in HQSAR. Combining the results of HQSAR and CoMSIA, the two groups were considered as the key groups associated with biological activity and the result can also be used to screen potent α-glucosidase inhibitors from various databases by virtual screening.</p></sec></sec>
<sec sec-type="conclusions">
<label>4.</label>
<title>Conclusions</title>
<p>In our research, 2D QSAR and 3D QSAR models have been successfully established to quantitatively describe the relationship between structures and activities of andrographolide derivatives as α-glucosidase inhibitors. The 2D QSAR model was based on the atomic connection of molecules and suggested that there might be three key groups associated with biological activity. Furthermore, the 3D QSAR model was based on molecular properties belonging to steric, hydrophobic and H-acceptor fields and indicated that compounds with structures fitting better into the 3D contour maps of model 16 had more potent activities. Combining 2D and 3D QSAR models, the key fragments and their spatial distribution could be efficiently identified. The convinced predictability of the model was demonstrated not only by internal validation but also by external validation using a test set. Overall, these results suggested that the developed QSAR model could be used to predict the inhibitory activities of unknown andrographolide derivatives on α-glucosidase. Application of this model would greatly facilitate the discovery of better α-glucosidase inhibitors.</p></sec></body>
<back>
<ack>
<p>This study was supported in part by grants from the China Natural Science Fund (30772642 and 30973618 to Y. W, and 30572209 and 30973565 to S. C) and the 211 project of Jinan University.</p></ack>
<ref-list>
<title>References and Notes</title>
<ref id="b1-ijms-11-00880"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>CY</given-names></name><name><surname>Tan</surname><given-names>BK</given-names></name></person-group><article-title>Effects of 14-deoxyandrographolide and 14-deoxy-11,12-didehydroandrographolide on nitric oxide production in cultured human endothelial cells</article-title><source>Phytother. Res</source><year>1999</year><volume>13</volume><fpage>157</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1099-1573(199903)13:2&lt;157::AID-PTR388&gt;3.0.CO;2-B</pub-id><pub-id pub-id-type="pmid">10190192</pub-id></citation></ref>
<ref id="b2-ijms-11-00880"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabu</surname><given-names>KK</given-names></name><name><surname>Padmesh</surname><given-names>P</given-names></name><name><surname>Seeni</surname><given-names>SJ</given-names></name></person-group><article-title>Intraspecific variation in active principle content and isozymes of Andrographis paniculata (kalmegh): A traditional hepatoprotective medicinal herb of India</article-title><source>Med. Aromat. Plant Sci</source><year>2001</year><volume>23</volume><fpage>637</fpage><lpage>647</lpage></citation></ref>
<ref id="b3-ijms-11-00880"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernacki</surname><given-names>RJ</given-names></name><name><surname>Niedbala</surname><given-names>MJ</given-names></name><name><surname>Korytnyk</surname><given-names>W</given-names></name></person-group><article-title>Glycosidases in cancer and invasion</article-title><source>Cancer Metastasis Rev</source><year>1985</year><volume>4</volume><fpage>81</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1007/BF00047738</pub-id><pub-id pub-id-type="pmid">3888385</pub-id></citation></ref>
<ref id="b4-ijms-11-00880"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pili</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Partis</surname><given-names>RA</given-names></name><name><surname>Mueller</surname><given-names>RA</given-names></name><name><surname>Chrest</surname><given-names>FJ</given-names></name><name><surname>Passaniti</surname><given-names>A</given-names></name></person-group><article-title>The alpha-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>2920</fpage><lpage>2926</lpage><pub-id pub-id-type="pmid">7540952</pub-id></citation></ref>
<ref id="b5-ijms-11-00880"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Humphries</surname><given-names>MJ</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>SL</given-names></name><name><surname>Olden</surname><given-names>K</given-names></name></person-group><article-title>Inhibition of experimental metastasis by castanospermine in mice: Blockage of two distinct stages of tumor colonization by oligosaccharide processing inhibitors</article-title><source>Cancer Res</source><year>1986</year><volume>46</volume><fpage>5215</fpage><lpage>5222</lpage><pub-id pub-id-type="pmid">3093061</pub-id></citation></ref>
<ref id="b6-ijms-11-00880"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papandreou</surname><given-names>MJ</given-names></name><name><surname>Barbouche</surname><given-names>R</given-names></name><name><surname>Guieu</surname><given-names>R</given-names></name><name><surname>Kieny</surname><given-names>MP</given-names></name><name><surname>Fenouillet</surname><given-names>E</given-names></name></person-group><article-title>The alpha-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step</article-title><source>Mol. Pharmacol</source><year>2002</year><volume>61</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1124/mol.61.1.186</pub-id><pub-id pub-id-type="pmid">11752220</pub-id></citation></ref>
<ref id="b7-ijms-11-00880"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ouzounov</surname><given-names>S</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Dwek</surname><given-names>RA</given-names></name><name><surname>Block</surname><given-names>TM</given-names></name><name><surname>Jordan</surname><given-names>R</given-names></name></person-group><article-title>The combination of interferon alpha-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) <italic>in vitro</italic>: Implications for hepatitis C virus (HCV) therapy</article-title><source>Antiviral Res</source><year>2002</year><volume>55</volume><fpage>425</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/S0166-3542(02)00075-X</pub-id><pub-id pub-id-type="pmid">12206880</pub-id></citation></ref>
<ref id="b8-ijms-11-00880"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>DD</given-names></name><name><surname>Frommer</surname><given-names>W</given-names></name><name><surname>Junge</surname><given-names>B</given-names></name><name><surname>Muller</surname><given-names>L</given-names></name><name><surname>Wingender</surname><given-names>W</given-names></name><name><surname>Truschei</surname><given-names>E</given-names></name><name><surname>Schafer</surname><given-names>D</given-names></name></person-group><article-title>Alpha-Glucosidase inhibitors. New complex oligosaccharides of microbial origin</article-title><source>Naturwissenschaften</source><year>1977</year><volume>64</volume><fpage>535</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1007/BF00483561</pub-id><pub-id pub-id-type="pmid">337162</pub-id></citation></ref>
<ref id="b9-ijms-11-00880"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kameda</surname><given-names>Y</given-names></name><name><surname>Asano</surname><given-names>N</given-names></name><name><surname>Yoshikawa</surname><given-names>M</given-names></name><name><surname>Takeucki</surname><given-names>M</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Matsui</surname><given-names>K</given-names></name><name><surname>Horii</surname><given-names>S</given-names></name><name><surname>Fukase</surname><given-names>HJ</given-names></name></person-group><article-title>Valiolamine, a new alpha-glucosidase inhibiting aminocyclitol produced by Streptomyces hygroscopicus</article-title><source>J.Antibiot</source><year>1984</year><volume>37</volume><fpage>1301</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.37.1301</pub-id><pub-id pub-id-type="pmid">6392268</pub-id></citation></ref>
<ref id="b10-ijms-11-00880"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>KM</given-names></name><name><surname>Begovic</surname><given-names>ME</given-names></name><name><surname>Rhinehart</surname><given-names>BL</given-names></name><name><surname>Heineke</surname><given-names>EW</given-names></name><name><surname>Ducep</surname><given-names>JB</given-names></name><name><surname>Kastner</surname><given-names>PR</given-names></name><name><surname>Marshall</surname><given-names>FN</given-names></name><name><surname>Danzin</surname><given-names>C</given-names></name></person-group><article-title>New potent alpha-glucohydrolase inhibitor MDL 73945 with long duration of action in rats</article-title><source>Diabetes</source><year>1991</year><volume>40</volume><fpage>825</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.2337/diabetes.40.7.825</pub-id><pub-id pub-id-type="pmid">2060719</pub-id></citation></ref>
<ref id="b11-ijms-11-00880"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujisawa</surname><given-names>T</given-names></name><name><surname>Ikegami</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Kawabata</surname><given-names>Y</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name></person-group><article-title>Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms</article-title><source>Metabolism</source><year>2005</year><volume>54</volume><fpage>387</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2004.10.004</pub-id><pub-id pub-id-type="pmid">15736118</pub-id></citation></ref>
<ref id="b12-ijms-11-00880"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van den Broek</surname><given-names>LAGM</given-names></name><name><surname>Kat-van den Nieuwenhof</surname><given-names>MW</given-names></name><name><surname>Butters</surname><given-names>TD</given-names></name><name><surname>van Boeckel</surname><given-names>CA</given-names></name></person-group><article-title>Synthesis of alpha-glucosidase I inhibitors showing antiviral (HIV-1) and immunosuppressive activity</article-title><source>J. Pharm. Pharmacol</source><year>1996</year><volume>48</volume><fpage>172</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.1996.tb07117.x</pub-id><pub-id pub-id-type="pmid">8935166</pub-id></citation></ref>
<ref id="b13-ijms-11-00880"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>GF</given-names></name><name><surname>Xu</surname><given-names>HW</given-names></name><name><surname>Wang</surname><given-names>JF</given-names></name><name><surname>Liu</surname><given-names>FW</given-names></name><name><surname>Liu</surname><given-names>HM</given-names></name></person-group><article-title>Studies on the novel alpha-glucosidase inhibitory activity and structure-activity relationships for andrographolide analogues</article-title><source>Bioorgan. Med. Chem</source><year>2006</year><volume>16</volume><fpage>2710</fpage><lpage>2713</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2006.02.011</pub-id></citation></ref>
<ref id="b14-ijms-11-00880"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>HW</given-names></name><name><surname>Dai</surname><given-names>GF</given-names></name><name><surname>Liu</surname><given-names>GZ</given-names></name><name><surname>Wang</surname><given-names>JF</given-names></name><name><surname>Liu</surname><given-names>HM</given-names></name></person-group><article-title>Synthesis of andrographolide derivatives: A new family of alpha-glucosidase inhibitors</article-title><source>Bioorgan. Med. Chem</source><year>2007</year><volume>15</volume><fpage>4247</fpage><lpage>4255</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2007.03.063</pub-id></citation></ref>
<ref id="b15-ijms-11-00880"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Truscheit</surname><given-names>E</given-names></name><name><surname>Frommer</surname><given-names>W</given-names></name><name><surname>Junge</surname><given-names>B</given-names></name><name><surname>Muller</surname><given-names>L</given-names></name><name><surname>Schmidt</surname><given-names>DD</given-names></name><name><surname>Wingender</surname><given-names>W</given-names></name></person-group><article-title>Chemistry and biochemistry of microbial alpha-glucosidase inhibitors</article-title><source>Angew. Chem</source><year>1981</year><volume>93</volume><fpage>738</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1002/ange.19810930905</pub-id></citation></ref>
<ref id="b16-ijms-11-00880"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Madariaga</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>PC</given-names></name><name><surname>Heitlinger</surname><given-names>LA</given-names></name><name><surname>Lenenthal</surname><given-names>M</given-names></name></person-group><article-title>Effects of graded alpha-glucosidase inhibition on sugar absorption <italic>in vivo</italic></article-title><source>Dig. Dis. Sci</source><year>1988</year><volume>33</volume><fpage>1020</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1007/BF01536000</pub-id><pub-id pub-id-type="pmid">3292164</pub-id></citation></ref>
<ref id="b17-ijms-11-00880"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>D-S</given-names></name><name><surname>Lee</surname><given-names>S-H</given-names></name></person-group><article-title>Genistein, a soy isoflavone, is a potent alpha-glucosidase inhibitor</article-title><source>FEBS Lett</source><year>2001</year><volume>501</volume><fpage>84</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(01)02631-X</pub-id><pub-id pub-id-type="pmid">11457461</pub-id></citation></ref>
<ref id="b18-ijms-11-00880"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCulloch</surname><given-names>DK</given-names></name><name><surname>Kurtz</surname><given-names>AB</given-names></name><name><surname>Tattersall</surname><given-names>RB</given-names></name></person-group><article-title>A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition</article-title><source>Diabetes Care</source><year>1983</year><volume>6</volume><fpage>483</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.2337/diacare.6.5.483</pub-id><pub-id pub-id-type="pmid">6400709</pub-id></citation></ref>
<ref id="b19-ijms-11-00880"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sou</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Yamasaki</surname><given-names>R</given-names></name><name><surname>Kagechika</surname><given-names>H</given-names></name><name><surname>Endo</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name></person-group><article-title>Alpha-glucosidase inhibitors with a 4,5,6,7-tetrachlorophthalimide skeleton pendanted with a cycloalkyl or dicarba-closo-dodecaborane group</article-title><source>Chem. Pharm. Bull</source><year>2001</year><volume>49</volume><fpage>791</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1248/cpb.49.791</pub-id><pub-id pub-id-type="pmid">11411542</pub-id></citation></ref>
<ref id="b20-ijms-11-00880"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Node</surname><given-names>K</given-names></name></person-group><article-title>Alpha-glucosidase inhibitors: New therapeutic agents for chronic heart failure</article-title><source>Hypertens. Res</source><year>2006</year><volume>29</volume><fpage>741</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1291/hypres.29.741</pub-id><pub-id pub-id-type="pmid">17283858</pub-id></citation></ref>
<ref id="b21-ijms-11-00880"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansch</surname><given-names>C</given-names></name><name><surname>Mahoney</surname><given-names>PP</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Muir</surname><given-names>RM</given-names></name></person-group><article-title>Correlation of biological activity of phenoxyacetic acids with Hammett substituent constants and partition coefficients</article-title><source>Nature</source><year>1962</year><volume>194</volume><fpage>178</fpage><lpage>180</lpage></citation></ref>
<ref id="b22-ijms-11-00880"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Itzstein</surname><given-names>VM</given-names></name><name><surname>Wu</surname><given-names>WY</given-names></name><name><surname>Kok</surname><given-names>GB</given-names></name></person-group><article-title>Rational design of potent sialidase-based inhibitors of influenza virus replication</article-title><source>Nature</source><year>1993</year><volume>363</volume><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1038/363418a0</pub-id><pub-id pub-id-type="pmid">8502295</pub-id></citation></ref>
<ref id="b23-ijms-11-00880"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melnick</surname><given-names>M</given-names></name><name><surname>Reich</surname><given-names>SH</given-names></name><name><surname>Lewis</surname><given-names>KK</given-names></name></person-group><article-title>Bis tertiary amide inhibitors of the HIV-1 protease generated <italic>via</italic> protein structure-based iterative design</article-title><source>J. Med. Chem</source><year>1996</year><volume>39</volume><fpage>2795</fpage><lpage>2811</lpage><pub-id pub-id-type="doi">10.1021/jm960092w</pub-id><pub-id pub-id-type="pmid">8709110</pub-id></citation></ref>
<ref id="b24-ijms-11-00880"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ring</surname><given-names>CS</given-names></name><name><surname>Sun</surname><given-names>E</given-names></name><name><surname>McKerrow</surname><given-names>JH</given-names></name></person-group><article-title>Structure-based inhibitor design by using protein models for the development of antiparasitic agents</article-title><source>Proc.Natl. Acad. Sci. USA</source><year>1993</year><volume>90</volume><fpage>3583</fpage><lpage>3587</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.8.3583</pub-id><pub-id pub-id-type="pmid">8475107</pub-id></citation></ref>
<ref id="b25-ijms-11-00880"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hibert</surname><given-names>MF</given-names></name><name><surname>Hoffmann</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>RC</given-names></name></person-group><article-title>Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site</article-title><source>J. Med. Chem</source><year>1990</year><volume>33</volume><fpage>1594</fpage><lpage>1600</lpage><pub-id pub-id-type="doi">10.1021/jm00168a011</pub-id><pub-id pub-id-type="pmid">2342053</pub-id></citation></ref>
<ref id="b26-ijms-11-00880"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Motoc</surname><given-names>I</given-names></name><name><surname>Sit</surname><given-names>SY</given-names></name><name><surname>Harte</surname><given-names>WE</given-names></name></person-group><article-title>3-Hydroxy-3-methylglutaryl-coenzyme. A reductase: Molecular modeling, three-dimensional structure-activity relationships, inhibitor design</article-title><source>Quant. Struct-Act. Relat</source><year>1991</year><volume>10</volume><fpage>30</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1002/qsar.19910100106</pub-id></citation></ref>
<ref id="b27-ijms-11-00880"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>B</given-names></name><name><surname>Gui</surname><given-names>CS</given-names></name><name><surname>Xu</surname><given-names>XY</given-names></name></person-group><article-title>Acta. A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening</article-title><source>Pharmacol. Sin</source><year>2003</year><volume>24</volume><fpage>497</fpage><lpage>504</lpage></citation></ref>
<ref id="b28-ijms-11-00880"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pastor</surname><given-names>M</given-names></name><name><surname>Cruciani</surname><given-names>G</given-names></name></person-group><article-title>A novel strategy for improving ligand selectivity in receptor-based drug design</article-title><source>J. Med. Chem</source><year>1995</year><volume>38</volume><fpage>4637</fpage><lpage>4647</lpage><pub-id pub-id-type="doi">10.1021/jm00023a003</pub-id><pub-id pub-id-type="pmid">7473591</pub-id></citation></ref>
<ref id="b29-ijms-11-00880"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>K</given-names></name><name><surname>Ziebuhr</surname><given-names>J</given-names></name><name><surname>Wadhwani</surname><given-names>P</given-names></name><name><surname>Mesters</surname><given-names>JR</given-names></name><name><surname>Hilgenfeld</surname><given-names>R</given-names></name></person-group><article-title>Coronavirus main proteinase (3CLpro) Structure: Basis for design of anti-SARS drugs</article-title><source>Science (Sciencexpress)</source><year>2003</year><volume>300</volume><fpage>1763</fpage><lpage>1767</lpage></citation></ref>
<ref id="b30-ijms-11-00880"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carlton</surname><given-names>AT</given-names></name><name><surname>Vinicius</surname><given-names>BDS</given-names></name><name><surname>Carlos</surname><given-names>HTD</given-names></name></person-group><article-title>Current topics in computer-aided drug design</article-title><source>J. Pharm. Sci</source><year>2008</year><volume>97</volume><fpage>1089</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1002/jps.21293</pub-id><pub-id pub-id-type="pmid">18214973</pub-id></citation></ref>
<ref id="b31-ijms-11-00880"><label>31.</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name></person-group>. The 3D-QSAR Studies on Andrographolide Derivatives Inhibiting α-Glucosidase. Ph.D. Dissertation. Zhengzhou University: Zhengzhou, China, <year>2006</year></citation></ref>
<ref id="b32-ijms-11-00880"><label>32.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Wolfgang</surname><given-names>H</given-names></name><name><surname>Léopold</surname><given-names>S</given-names></name></person-group><source>Applied Multivariate Statistical Analysis</source><edition>2nd ed</edition><publisher-name>Springer Press</publisher-name><publisher-loc>Berlin, Heidelberg, Germany</publisher-loc><year>2007</year><fpage>233</fpage><lpage>272</lpage></citation></ref>
<ref id="b33-ijms-11-00880"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ash</surname><given-names>S</given-names></name><name><surname>Cline</surname><given-names>MA</given-names></name><name><surname>Homer</surname><given-names>RW</given-names></name><name><surname>Hurst</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>GB</given-names></name></person-group><article-title>SYBYL line notation (SLN): A versatile language for chemical structure representation</article-title><source>J Chem Inf Comput Sci</source><year>1997</year><volume>37</volume><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1021/ci960109j</pub-id></citation></ref>
<ref id="b34-ijms-11-00880"><label>34.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Timothy</surname><given-names>EL</given-names></name></person-group><source>VAX Architecture Reference Manual</source><publisher-name>Digital Press</publisher-name><publisher-loc>Newton, MA, USA</publisher-loc><year>1987</year><fpage>288</fpage><lpage>326</lpage></citation></ref>
<ref id="b35-ijms-11-00880"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>IE</given-names></name><name><surname>Feikama</surname><given-names>J</given-names></name><name><surname>Constantine</surname><given-names>N</given-names></name><name><surname>Kowalski</surname><given-names>BR</given-names></name></person-group><article-title>Prediction of Product Quality from Spectral Data Using the Partial Least-Squares Method</article-title><source>J. Chem. Inf. Comput. Sci</source><year>1984</year><volume>24</volume><fpage>20</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1021/ci00041a602</pub-id></citation></ref>
<ref id="b36-ijms-11-00880"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Golbraikh</surname><given-names>A</given-names></name><name><surname>Tropsha</surname><given-names>A</given-names></name></person-group><article-title>Beware of q2!</article-title><source>J. Mol. Graph. Model</source><year>2002</year><volume>20</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/S1093-3263(01)00123-1</pub-id><pub-id pub-id-type="pmid">11858635</pub-id></citation></ref>
<ref id="b37-ijms-11-00880"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cramer</surname><given-names>RD</given-names></name><name><surname>Patterson</surname><given-names>DE</given-names></name><name><surname>Bunce</surname><given-names>JD</given-names></name></person-group><article-title>Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins</article-title><source>J. Am. Chem. Soc</source><year>1988</year><volume>110</volume><fpage>5959</fpage><lpage>5967</lpage><pub-id pub-id-type="doi">10.1021/ja00226a005</pub-id><pub-id pub-id-type="pmid">22148765</pub-id></citation></ref>
<ref id="b38-ijms-11-00880"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klebe</surname><given-names>G</given-names></name><name><surname>Abraham</surname><given-names>U</given-names></name></person-group><article-title>Comparative Molecular Similarity Index Analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries</article-title><source>J. Comput. Aided Mol. Design</source><year>1999</year><volume>13</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1023/A:1008047919606</pub-id></citation></ref>
<ref id="b39-ijms-11-00880"><label>39.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>van de Waterbeemd</surname><given-names>H</given-names></name></person-group><source>Chemometric Methods in Molecular Design (Methods and Principles in Medicinal Chemistry)</source><publisher-name>Wiley-VCH Press</publisher-name><publisher-loc>Weinheim, Germany</publisher-loc><year>1995</year><fpage>309</fpage><lpage>318</lpage></citation></ref>
<ref id="b40-ijms-11-00880"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dixit</surname><given-names>A</given-names></name><name><surname>Kashaw</surname><given-names>SK</given-names></name><name><surname>Gaur</surname><given-names>S</given-names></name><name><surname>Saxena</surname><given-names>AK</given-names></name></person-group><article-title>Development of CoMFA, advance CoMFA and CoMSIA models in pyrroloquinazolines as thrombin receptor antagonist</article-title><source>Bioorgan. Med. Chem</source><year>2004</year><volume>12</volume><fpage>3591</fpage><lpage>3598</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2004.04.016</pub-id></citation></ref>
<ref id="b41-ijms-11-00880"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Narayanan</surname><given-names>R</given-names></name><name><surname>Gunturi</surname><given-names>SB</given-names></name></person-group><article-title>In silico ADME modelling: Prediction models for blood-brain barrier permeation using a systematic variable selection method</article-title><source>Bioorgan. Med. Chem</source><year>2005</year><volume>13</volume><fpage>3017</fpage><lpage>3028</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2005.01.061</pub-id></citation></ref>
<ref id="b42-ijms-11-00880"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gunturi</surname><given-names>SB</given-names></name><name><surname>Narayanan</surname><given-names>R</given-names></name><name><surname>Khandelwal</surname><given-names>A</given-names></name></person-group><article-title>In silico ADME modelling: Computational models to predict human serum albumin binding affinity using ant colony systems</article-title><source>Bioorgan. Med. Chem</source><year>2006</year><volume>14</volume><fpage>4118</fpage><lpage>4129</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2006.02.008</pub-id></citation></ref>
<ref id="b43-ijms-11-00880"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gunturi</surname><given-names>SB</given-names></name><name><surname>Narayanan</surname><given-names>R</given-names></name></person-group><article-title>In silico ADME modeling 3: Computational models to predict human intestinal absorption using sphere exclusion and kNN QSAR methods</article-title><source>QSAR Comb. Sci</source><year>2007</year><volume>26</volume><fpage>653</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1002/qsar.200630094</pub-id></citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figures and Tables</title>
<fig id="f1-ijms-11-00880" position="float">
<label>Figure 1.</label>
<caption>
<p>Formulae of the studied andrographolide derivatives.</p></caption><graphic xlink:href="ijms-11-00880f1a.gif"/><graphic xlink:href="ijms-11-00880f1b.gif"/><graphic xlink:href="ijms-11-00880f1c.gif"/></fig>
<fig id="f2-ijms-11-00880" position="float">
<label>Figure 2.</label>
<caption>
<p>PCA plot for studied compounds <bold>1</bold>–<bold>25</bold>.</p></caption><graphic xlink:href="ijms-11-00880f2.gif"/></fig>
<fig id="f3-ijms-11-00880" position="float">
<label>Figure 3.</label>
<caption>
<p>Key fragments of 2D-QSAR Model.</p></caption><graphic xlink:href="ijms-11-00880f3.gif"/></fig>
<fig id="f4-ijms-11-00880" position="float">
<label>Figure 4.</label>
<caption>
<p>Structure of andrographolide.</p></caption><graphic xlink:href="ijms-11-00880f4.gif"/></fig>
<fig id="f5-ijms-11-00880" position="float">
<label>Figure 5.</label>
<caption>
<p>Alignment of the database.</p></caption><graphic xlink:href="ijms-11-00880f5.gif"/></fig>
<fig id="f6-ijms-11-00880" position="float">
<label>Figure 6.</label>
<caption>
<p>Compound <bold>21</bold> placed in the H-accept contour map.</p></caption><graphic xlink:href="ijms-11-00880f6.gif"/></fig>
<fig id="f7-ijms-11-00880" position="float">
<label>Figure 7.</label>
<caption>
<p>Compound <bold>21</bold> placed in the hydrophobic contour map.</p></caption><graphic xlink:href="ijms-11-00880f7.gif"/></fig>
<fig id="f8-ijms-11-00880" position="float">
<label>Figure 8.</label>
<caption>
<p>Compound <bold>21</bold> was placed in the steric contour map.</p></caption><graphic xlink:href="ijms-11-00880f8.gif"/></fig>
<table-wrap id="t1-ijms-11-00880" position="float">
<label>Table 1.</label>
<caption>
<p>Comparison of the predicted PLogIC50 of database with the experimental values by using 2D-QSAR Model.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="middle" align="left"><bold>Compound</bold></th>
<th valign="middle" align="left"><bold>ACT<xref ref-type="table-fn" rid="tfn1-ijms-11-00880">a</xref></bold></th>
<th valign="middle" align="left"><bold>PRE<xref ref-type="table-fn" rid="tfn2-ijms-11-00880">b</xref></bold></th>
<th valign="middle" align="left"><bold>|Δ|<xref ref-type="table-fn" rid="tfn3-ijms-11-00880">c</xref></bold></th>
<th valign="middle" align="left"><bold>Compound</bold></th>
<th valign="middle" align="left"><bold>ACT</bold></th>
<th valign="middle" align="left"><bold>PRE</bold></th>
<th valign="middle" align="left"><bold>|Δ|</bold></th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">1</td>
<td valign="top" align="left">4.000</td>
<td valign="top" align="left">3.933</td>
<td valign="top" align="left">0.067</td>
<td valign="top" align="left">2</td>
<td valign="top" align="left">4.000</td>
<td valign="top" align="left">3.995</td>
<td valign="top" align="left">0.05</td></tr>
<tr>
<td valign="top" align="left">3</td>
<td valign="top" align="left">3.959</td>
<td valign="top" align="left">3.876</td>
<td valign="top" align="left">0.109</td>
<td valign="top" align="left">4</td>
<td valign="top" align="left">3.959</td>
<td valign="top" align="left">4.054</td>
<td valign="top" align="left">0.095</td></tr>
<tr>
<td valign="top" align="left">5</td>
<td valign="top" align="left">-</td>
<td valign="top" align="left">-</td>
<td valign="top" align="left">-<xref ref-type="table-fn" rid="tfn4-ijms-11-00880">d</xref></td>
<td valign="top" align="left">6</td>
<td valign="top" align="left">4.237</td>
<td valign="top" align="left">4.139</td>
<td valign="top" align="left">0.098</td></tr>
<tr>
<td valign="top" align="left">7</td>
<td valign="top" align="left">4.237</td>
<td valign="top" align="left">4.159</td>
<td valign="top" align="left">0.078</td>
<td valign="top" align="left">8</td>
<td valign="top" align="left">4.076</td>
<td valign="top" align="left">4.087</td>
<td valign="top" align="left">0.011</td></tr>
<tr>
<td valign="top" align="left">9</td>
<td valign="top" align="left">4.155</td>
<td valign="top" align="left">4.061</td>
<td valign="top" align="left">0.094</td>
<td valign="top" align="left">10</td>
<td valign="top" align="left">4.000</td>
<td valign="top" align="left">4.099</td>
<td valign="top" align="left">0.099</td></tr>
<tr>
<td valign="top" align="left">11</td>
<td valign="top" align="left">4.000</td>
<td valign="top" align="left">4.089</td>
<td valign="top" align="left">0.089</td>
<td valign="top" align="left">12</td>
<td valign="top" align="left">-</td>
<td valign="top" align="left">-</td>
<td valign="top" align="left">-<xref ref-type="table-fn" rid="tfn4-ijms-11-00880">d</xref></td></tr>
<tr>
<td valign="top" align="left">13</td>
<td valign="top" align="left">3.959</td>
<td valign="top" align="left">4.176</td>
<td valign="top" align="left">0.217</td>
<td valign="top" align="left">14</td>
<td valign="top" align="left">4.000</td>
<td valign="top" align="left">3.946</td>
<td valign="top" align="left">0.054</td></tr>
<tr>
<td valign="top" align="left">15</td>
<td valign="top" align="left">3.983</td>
<td valign="top" align="left">3.924</td>
<td valign="top" align="left">0.059</td>
<td valign="top" align="left">16</td>
<td valign="top" align="left">3.921</td>
<td valign="top" align="left">3.961</td>
<td valign="top" align="left">0.040</td></tr>
<tr>
<td valign="top" align="left">17</td>
<td valign="top" align="left">3.996</td>
<td valign="top" align="left">3.954</td>
<td valign="top" align="left">0.042</td>
<td valign="top" align="left">18</td>
<td valign="top" align="left">3.971</td>
<td valign="top" align="left">3.902</td>
<td valign="top" align="left">0.069</td></tr>
<tr>
<td valign="top" align="left">19</td>
<td valign="top" align="left">4.553</td>
<td valign="top" align="left">4.686</td>
<td valign="top" align="left">0.133</td>
<td valign="top" align="left">20</td>
<td valign="top" align="left">4.796</td>
<td valign="top" align="left">4.813</td>
<td valign="top" align="left">0.017</td></tr>
<tr>
<td valign="top" align="left">21</td>
<td valign="top" align="left">5.222</td>
<td valign="top" align="left">4.806</td>
<td valign="top" align="left">0.416</td>
<td valign="top" align="left">22</td>
<td valign="top" align="left">4.854</td>
<td valign="top" align="left">4.798</td>
<td valign="top" align="left">0.056</td></tr>
<tr>
<td valign="top" align="left">23</td>
<td valign="top" align="left">4.602</td>
<td valign="top" align="left">4.715</td>
<td valign="top" align="left">0.113</td>
<td valign="top" align="left">24</td>
<td valign="top" align="left">4.444</td>
<td valign="top" align="left">4.745</td>
<td valign="top" align="left">0.301</td></tr>
<tr>
<td valign="top" align="left">25</td>
<td valign="top" align="left">4.959</td>
<td valign="top" align="left">4.698</td>
<td valign="top" align="left">0.261</td><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-ijms-11-00880">
<label>a:</label>
<p>Experimental data (PLogIC<sub>50</sub>)</p></fn><fn id="tfn2-ijms-11-00880">
<label>b:</label>
<p>Predicted data (PLogIC<sub>50</sub>)</p></fn><fn id="tfn3-ijms-11-00880">
<label>c:</label>
<p>|a–b|</p></fn><fn id="tfn4-ijms-11-00880">
<label>d:</label>
<p>Outline compounds.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="t2-ijms-11-00880" position="float">
<label>Table 2.</label>
<caption>
<p>Comparison of different 3D-QSAR models.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="middle" align="left"><bold>No.</bold></th>
<th valign="middle" align="left"><bold>Method</bold></th>
<th valign="middle" align="left"><bold>Field<xref ref-type="table-fn" rid="tfn5-ijms-11-00880">a</xref></bold></th>
<th valign="middle" align="left"><bold>OC<xref ref-type="table-fn" rid="tfn6-ijms-11-00880">b</xref></bold></th>
<th valign="middle" align="left"><bold>(q<sup>2</sup>)<xref ref-type="table-fn" rid="tfn7-ijms-11-00880">c</xref></bold></th>
<th valign="middle" align="left"><bold>SE<xref ref-type="table-fn" rid="tfn8-ijms-11-00880">d</xref></bold></th>
<th valign="middle" align="left"><bold>(R<sup>2</sup>)<xref ref-type="table-fn" rid="tfn9-ijms-11-00880">e</xref></bold></th>
<th valign="middle" align="left"><bold>F</bold></th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">1</td>
<td valign="top" align="left">CoMFA</td>
<td valign="top" align="left">S+E</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0.741</td>
<td valign="top" align="left">0.178</td>
<td valign="top" align="left">0.819</td>
<td valign="top" align="left">67.905</td></tr>
<tr>
<td valign="top" align="left" colspan="8"><hr/></td></tr>
<tr>
<td valign="top" align="left">2</td><td valign="top" align="left"/>
<td valign="top" align="left">S</td>
<td valign="top" align="left">2</td>
<td valign="top" align="left">0.748</td>
<td valign="top" align="left">0.159</td>
<td valign="top" align="left">0.866</td>
<td valign="top" align="left">45.280</td></tr>
<tr>
<td valign="top" align="left">3</td><td valign="top" align="left"/>
<td valign="top" align="left">E</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0.710</td>
<td valign="top" align="left">0.187</td>
<td valign="top" align="left">0.802</td>
<td valign="top" align="left">60.592</td></tr>
<tr>
<td valign="top" align="left">4</td><td valign="top" align="left"/>
<td valign="top" align="left">H</td>
<td valign="top" align="left">2</td>
<td valign="top" align="left">0.771</td>
<td valign="top" align="left">0.132</td>
<td valign="top" align="left">0.907</td>
<td valign="top" align="left">68.505</td></tr>
<tr>
<td valign="top" align="left">5</td><td valign="top" align="left"/>
<td valign="top" align="left">D</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0.313</td>
<td valign="top" align="left">0.297</td>
<td valign="top" align="left">0.498</td>
<td valign="top" align="left">14.876</td></tr>
<tr>
<td valign="top" align="left">6</td><td valign="top" align="left"/>
<td valign="top" align="left">A</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0.724</td>
<td valign="top" align="left">0.184</td>
<td valign="top" align="left">0.807</td>
<td valign="top" align="left">62.902</td></tr>
<tr>
<td valign="top" align="left">7</td><td valign="top" align="left"/>
<td valign="top" align="left">S+E</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0.732</td>
<td valign="top" align="left">0.182</td>
<td valign="top" align="left">0.812</td>
<td valign="top" align="left">64.778</td></tr>
<tr>
<td valign="top" align="left">8</td>
<td valign="top" align="left">CoMSIA</td>
<td valign="top" align="left">S+H</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0.774</td>
<td valign="top" align="left">0.148</td>
<td valign="top" align="left">0.875</td>
<td valign="top" align="left">105.050</td></tr>
<tr>
<td valign="top" align="left">9</td><td valign="top" align="left"/>
<td valign="top" align="left">S+A</td>
<td valign="top" align="left">2</td>
<td valign="top" align="left">0.738</td>
<td valign="top" align="left">0.159</td>
<td valign="top" align="left">0.866</td>
<td valign="top" align="left">45.251</td></tr>
<tr>
<td valign="top" align="left">10</td><td valign="top" align="left"/>
<td valign="top" align="left">S+E+H</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0.755</td>
<td valign="top" align="left">0.169</td>
<td valign="top" align="left">0.838</td>
<td valign="top" align="left">77.788</td></tr>
<tr>
<td valign="top" align="left">11</td><td valign="top" align="left"/>
<td valign="top" align="left">S+H+A</td>
<td valign="top" align="left">2</td>
<td valign="top" align="left">0.759</td>
<td valign="top" align="left">0.130</td>
<td valign="top" align="left">0.910</td>
<td valign="top" align="left">70.509</td></tr>
<tr>
<td valign="top" align="left">12</td><td valign="top" align="left"/>
<td valign="top" align="left">S+E+H+A</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0.747</td>
<td valign="top" align="left">0.174</td>
<td valign="top" align="left">0.829</td>
<td valign="top" align="left">72.588</td></tr>
<tr>
<td valign="top" align="left">13<xref ref-type="table-fn" rid="tfn10-ijms-11-00880">f</xref></td><td valign="top" align="left"/>
<td valign="top" align="left">H(Focus)</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0.776</td>
<td valign="top" align="left">0.144</td>
<td valign="top" align="left">0.882</td>
<td valign="top" align="left">112.028</td></tr>
<tr>
<td valign="top" align="left">14<sup>f</sup></td><td valign="top" align="left"/>
<td valign="top" align="left">S+H(Focus)</td>
<td valign="top" align="left">2</td>
<td valign="top" align="left">0.772</td>
<td valign="top" align="left">0.1.43</td>
<td valign="top" align="left">0.891</td>
<td valign="top" align="left">57.188</td></tr>
<tr>
<td valign="top" align="left">15<xref ref-type="table-fn" rid="tfn10-ijms-11-00880">f</xref></td><td valign="top" align="left"/>
<td valign="top" align="left">S+E+H(Focus)</td>
<td valign="top" align="left">2</td>
<td valign="top" align="left">0.763</td>
<td valign="top" align="left">0.148</td>
<td valign="top" align="left">0.884</td>
<td valign="top" align="left">53.422</td></tr>
<tr>
<td valign="top" align="left">16<xref ref-type="table-fn" rid="tfn10-ijms-11-00880">f</xref></td><td valign="top" align="left"/>
<td valign="top" align="left">S+H+A(Focus)</td>
<td valign="top" align="left">2</td>
<td valign="top" align="left">0.794</td>
<td valign="top" align="left">0.127</td>
<td valign="top" align="left">0.915</td>
<td valign="top" align="left">75.093</td></tr>
<tr><td valign="top" align="left"/>
<td valign="top" align="left">Y-Random</td>
<td valign="top" align="left">S+H+A(Focus)</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0.199</td>
<td valign="top" align="left">-</td>
<td valign="top" align="left">-</td>
<td valign="top" align="left">-</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn5-ijms-11-00880">
<label>a:</label>
<p>S: Steric field, E: Electrostatic field, H: Hydrophobic field.</p></fn><fn id="tfn6-ijms-11-00880">
<p>D: H-donor field, A: H-acceptor field.</p></fn><fn id="tfn7-ijms-11-00880">
<label>b:</label>
<p>Optimum of component.</p></fn><fn id="tfn8-ijms-11-00880">
<label>c:</label>
<p>The models’ cross-validation r<sup>2</sup>.</p></fn><fn id="tfn9-ijms-11-00880">
<label>d:</label>
<p>Standard Error.</p></fn><fn id="tfn10-ijms-11-00880">
<label>e:</label>
<p>Correlation coefficient between predicted and experimental PLogIC50 of 18 compounds.</p></fn><fn id="tfn11-ijms-11-00880">
<label>f:</label>
<p>The model was optimized by Focus Method.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="t3-ijms-11-00880" position="float">
<label>Table 3.</label>
<caption>
<p>Correlation coefficient between predicted and experimental PLogIC50 of the test set by model <bold>13</bold>, <bold>8</bold>, <bold>15</bold>, and <bold>16.</bold></p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="middle" align="left"><bold>No.</bold></th>
<th valign="middle" align="left"><bold>Models</bold></th>
<th valign="middle" align="left"><bold>R<sup>2</sup></bold></th>
<th valign="middle" align="left"><bold>Slope</bold></th>
<th valign="middle" align="left"><bold>SE</bold></th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">13</td>
<td valign="top" align="left">H(Focus)</td>
<td valign="top" align="left">0.906</td>
<td valign="top" align="left">1.007</td>
<td valign="top" align="left">0.143</td></tr>
<tr>
<td valign="top" align="left">8</td>
<td valign="top" align="left">S+H</td>
<td valign="top" align="left">0.927</td>
<td valign="top" align="left">0.974</td>
<td valign="top" align="left">0.121</td></tr>
<tr>
<td valign="top" align="left">15</td>
<td valign="top" align="left">S+E+H(Focus)</td>
<td valign="top" align="left">0.895</td>
<td valign="top" align="left">0.937</td>
<td valign="top" align="left">0.142</td></tr>
<tr>
<td valign="top" align="left">16</td>
<td valign="top" align="left">S+H+A(Focus)</td>
<td valign="top" align="left">0.941</td>
<td valign="top" align="left">0.933</td>
<td valign="top" align="left">0.104</td></tr></tbody></table></table-wrap>
<table-wrap id="t4-ijms-11-00880" position="float">
<label>Table 4.</label>
<caption>
<p>Comparison between predicted PLogIC50 of database and experimental values by using Model <bold>16</bold>.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="middle" align="left"><bold>Compound</bold></th>
<th valign="middle" align="left"><bold>ACT<xref ref-type="table-fn" rid="tfn12-ijms-11-00880">a</xref></bold></th>
<th valign="middle" align="left"><bold>PRE<xref ref-type="table-fn" rid="tfn13-ijms-11-00880">b</xref></bold></th>
<th valign="middle" align="left"><bold>|Δ|<xref ref-type="table-fn" rid="tfn14-ijms-11-00880">c</xref></bold></th>
<th valign="middle" align="left"><bold>Compound</bold></th>
<th valign="middle" align="left"><bold>ACT</bold></th>
<th valign="middle" align="left"><bold>PRE</bold></th>
<th valign="middle" align="left"><bold>|Δ|</bold></th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">1</td>
<td valign="top" align="left">3.996</td>
<td valign="top" align="left">3.960</td>
<td valign="top" align="left">0.04</td>
<td valign="top" align="left">2</td>
<td valign="top" align="left">4.000</td>
<td valign="top" align="left">3.960</td>
<td valign="top" align="left">0.04</td></tr>
<tr>
<td valign="top" align="left">3</td>
<td valign="top" align="left">3.959</td>
<td valign="top" align="left">3.970</td>
<td valign="top" align="left">0.011</td>
<td valign="top" align="left">4</td>
<td valign="top" align="left">3.959</td>
<td valign="top" align="left">3.999</td>
<td valign="top" align="left">0.04</td></tr>
<tr>
<td valign="top" align="left">5</td>
<td valign="top" align="left">-</td>
<td valign="top" align="left">-</td>
<td valign="top" align="left">-<xref ref-type="table-fn" rid="tfn15-ijms-11-00880">d</xref></td>
<td valign="top" align="left">6</td>
<td valign="top" align="left">4.237</td>
<td valign="top" align="left">4.238</td>
<td valign="top" align="left">0.001</td></tr>
<tr>
<td valign="top" align="left">7</td>
<td valign="top" align="left">4.237</td>
<td valign="top" align="left">4.204</td>
<td valign="top" align="left">0.033</td>
<td valign="top" align="left">8</td>
<td valign="top" align="left">4.076</td>
<td valign="top" align="left">4.016</td>
<td valign="top" align="left">0.06</td></tr>
<tr>
<td valign="top" align="left">9</td>
<td valign="top" align="left">4.155</td>
<td valign="top" align="left">4.179</td>
<td valign="top" align="left">0.029</td>
<td valign="top" align="left">10</td>
<td valign="top" align="left">4.000</td>
<td valign="top" align="left">4.119</td>
<td valign="top" align="left">0.119</td></tr>
<tr>
<td valign="top" align="left">11</td>
<td valign="top" align="left">4.000</td>
<td valign="top" align="left">3.935</td>
<td valign="top" align="left">0.065</td>
<td valign="top" align="left">12</td>
<td valign="top" align="left">-</td>
<td valign="top" align="left">-</td>
<td valign="top" align="left">-</td></tr>
<tr>
<td valign="top" align="left">13</td>
<td valign="top" align="left">3.959</td>
<td valign="top" align="left">4.111</td>
<td valign="top" align="left">0.152</td>
<td valign="top" align="left">14</td>
<td valign="top" align="left">4.000</td>
<td valign="top" align="left">4.150</td>
<td valign="top" align="left">0.150</td></tr>
<tr>
<td valign="top" align="left">15</td>
<td valign="top" align="left">3.983</td>
<td valign="top" align="left">4.112</td>
<td valign="top" align="left">0.129</td>
<td valign="top" align="left">16</td>
<td valign="top" align="left">3.921</td>
<td valign="top" align="left">4.075</td>
<td valign="top" align="left">0.154</td></tr>
<tr>
<td valign="top" align="left">17</td>
<td valign="top" align="left">3.996</td>
<td valign="top" align="left">3.916</td>
<td valign="top" align="left">0.08</td>
<td valign="top" align="left">18</td>
<td valign="top" align="left">3.971</td>
<td valign="top" align="left">3.903</td>
<td valign="top" align="left">0.068</td></tr>
<tr>
<td valign="top" align="left">19</td>
<td valign="top" align="left">4.553</td>
<td valign="top" align="left">4.621</td>
<td valign="top" align="left">0.068</td>
<td valign="top" align="left">20</td>
<td valign="top" align="left">4.796</td>
<td valign="top" align="left">4.863</td>
<td valign="top" align="left">0.068</td></tr>
<tr>
<td valign="top" align="left">21</td>
<td valign="top" align="left">5.222</td>
<td valign="top" align="left">5.067</td>
<td valign="top" align="left">0.155</td>
<td valign="top" align="left">22</td>
<td valign="top" align="left">4.854</td>
<td valign="top" align="left">4.886</td>
<td valign="top" align="left">0.032</td></tr>
<tr>
<td valign="top" align="left">23</td>
<td valign="top" align="left">4.602</td>
<td valign="top" align="left">4.831</td>
<td valign="top" align="left">0.229</td>
<td valign="top" align="left">24</td>
<td valign="top" align="left">4.444</td>
<td valign="top" align="left">4.481</td>
<td valign="top" align="left">0.037</td></tr>
<tr>
<td valign="top" align="left">25</td>
<td valign="top" align="left">4.959</td>
<td valign="top" align="left">4.698</td>
<td valign="top" align="left">0.261</td><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/></tr></tbody></table>
<table-wrap-foot><fn id="tfn12-ijms-11-00880">
<label>a:</label>
<p>Experimental data (PLogIC<sub>50</sub>)</p></fn><fn id="tfn13-ijms-11-00880">
<label>b:</label>
<p>Predicted data (PLogIC<sub>50</sub>)</p></fn><fn id="tfn14-ijms-11-00880">
<label>c:</label>
<p>|a–b|</p></fn><fn id="tfn15-ijms-11-00880">
<label>d:</label>
<p>Outline compounds</p></fn></table-wrap-foot></table-wrap></sec></back></article>
